Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05767008
Other study ID # 43-692
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 1, 2021
Est. completion date April 1, 2022

Study information

Verified date March 2023
Source Nanometics (d.b.a. PHD Biosciences)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed to determine the Sun Protection Factor (SPF) of a test product following 80 Minute Water Immersion methodology defined in Final Monograph - Code of Federal Regulations Title 21 - "Labeling and Effectiveness Testing; Sunscreen Drug Products; Required Labeling Based on Effectiveness Testing", Final Rule, 21 CFR 201.327.(j)


Description:

All studies will be carried out in a blind fashion according to FDA guidelines, which describes the number of subjects required to satisfy FDA guidelines and labeling requirements of sunscreens. Human subject selection: Healthy volunteers (n=25) free from systemic or dermatological disorders of Fitzpatrick skin type I, II or III (12 male and 13 female; ages 18 through 55) will be recruited. Rectangular test sites of (30 cm2) on the infrascapular area of the back will be delineated, and inspected to ensure uniform pigmentation, skin tone and texture, and absence of warts, moles, nevi, scars, blemishes and active dermal lesions. SPF determination: A 150 W Xenon Arc Solar Simulator, which produces a continuous UV spectra substantially equivalent to that of natural sunlight will be used and UVB radiation monitored continuously. Measurements will be recorded within 8 mm from the surface of the skin, and the size of the exposure site will be ≥ 0.5 cm2. The Sunscreen or a positive control (8% homosalate) will be applied to subjects evenly in the delineated areas at 2 mg/cm2. Following static exposures, test sample and water resistant controls will be applied on adjacent sites for testing. An unprotected site will receive a series of five UV exposures based upon the previously determined Minimal Erythemal Dose (MED). The UV exposures for each formulation, will be calculated from previously determined MED and the intended SPF. Immersion procedure: Immersion will be conducted in a whirlpool tub with room temperature water circulating at 3450 r.p.m. Following pre-immersion SPF measurements, volunteers will be subjected to 80 min of whirlpool immersion, with SPF measurements taken after air drying at 20, 40, and 80, min. c. Data Analysis and Interpretation: The 80 min time point is chosen as a benchmark for success because the FDA only permits finished sunscreen products to be labeled as water resistant for up to 80 min. All subjects will return to the laboratory sixteen to twenty-four hours post-exposure for a blinded determination of erythema responses, the mean SPF, standard deviation (s) value, and standard error (SE). No attempts to determine the influence of sex or age on the interpretation of results will be undertaken because of Phase I SBIR budgetary and time limitations, and because this is not a requirement of FDA or customers / distribution partners who will purchase the product. The standard deviation (s) will be determined and the upper 5% point was obtained from the t distribution table with n-1 degrees of freedom (t).


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date April 1, 2022
Est. primary completion date April 1, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: 1. Males (n=12) and females (n=13) 18 through 55 years. 2. Fitzpatrick skin type I, II or III. 3. Free from dermatological disorders. Exclusion Criteria: 1. Volunteers younger than 18 years, or older than 55 years. 2. Volunteers of Fitzpatrick skin type IV or greater. 3. Volunteers with dermatological disorders or the presence of non-uniform pigmentation, skin tone and texture, warts, moles, nevi, scars, blemishes and active dermal lesions at the desired test sites. 4. Volunteers being treated with photosensitizing agents, or have been treated with photosensitizing agents in the prior 6 months

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Sunscreen -R43
Long wear metal oxide particles

Locations

Country Name City State
United States Nanometics La Jolla California

Sponsors (1)

Lead Sponsor Collaborator
Nanometics (d.b.a. PHD Biosciences)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary SPF determination SPF determination before and after water immersion 80 minutes
See also
  Status Clinical Trial Phase
Recruiting NCT00206882 - The Sun Protection Effect and Efficacy in Treatment of Sunburn Using Topical Corticosteroids. N/A
Completed NCT00441051 - Efficacy and Safety of Diclofenac Sodium (0.1%) Gel in Patients With UV Induced Painful Sunburn Phase 3
Completed NCT01873430 - The Sun Protective Effect of Melatonin Phase 1
Completed NCT00326274 - Clinical Safety Trial of Long-Term Intermittent Use of Helioblock® SX Cream Phase 3
Completed NCT03199573 - Hats on Head Start: A A Survey of Sun Protection Behaviors in Head Start and Other Early Childhood Education Programs N/A
Terminated NCT03332524 - Clinical Trial of the Safety and Efficacy of SP160412 in the Temporary Relief of Mild to Moderate Sunburn Phase 2
Completed NCT03752736 - Sun Safety Skills for Elementary School Students N/A
Completed NCT05260359 - Dermal Irritation, Sensitization and Cumulative Irritation Potential of 6% Bemotrizinol Phase 2
Completed NCT01021787 - Dermal Penetration of the Titanium Dioxide in Anthelios SX SPF40 Cream Phase 4
Completed NCT03607578 - Test of Interventions to Prevent Skin Cancer Among Danes on Vacation in High UV Index Sunny Destinations N/A
Completed NCT03489356 - Project Options - The ABC Method N/A
Enrolling by invitation NCT03007589 - Natural Sunlight Protection and Simulated Sunlight Protection Offered by Sunscreens and Fabrics N/A
Not yet recruiting NCT01237925 - Non-inferiority Clinical Trial of Dexchlorpheniramine (Cream Versus Gel) in the Relief of Sunburn Related Symptoms Phase 3
Not yet recruiting NCT01085851 - Non-inferiority Clinical Trial of Dexchlorpheniramine (Cream Versus Lotion) in the Relief of Sunburn Related Symptoms Phase 3